<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03249064</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-VIT-2015-69</org_study_id>
    <nct_id>NCT03249064</nct_id>
  </id_info>
  <brief_title>Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo</brief_title>
  <official_title>Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate some differences in the immune system between patients with
      vitiligo and patients without the disease.

      These differences will be evaluated by the extraction of peripheral blood that will be
      analyzed before the treatment and after the treatment that, in the habitual way and at the
      discretion of the responsible dermatologist.

      Patients agreeing to participate in the study will be subjected to extraction of two tubes
      (20 ml) of peripheral blood (baseline) and after 12 weeks (+/- 5 days) of treatment.

      Therefore, neither treatment nor follow-up visits will be modified by participation, but will
      be the same whether or not participate in the study.

      In the case of controls, two peripheral blood tubes (20ml) will be removed in a single
      participation.

      Patients with vitiligo will also be asked to complete questionnaires to measure stress,
      depression and perception of disease (PSS-10, Skindex-29, HADS, Likert) before and after 12
      weeks (+/- 5 days) of therapeutic intervention .

      This study will include 20 patients with active non-segmental vitiligo and 10 controls
      without the disease. The duration of participation in this study will be 12 weeks (+/- 5
      days) for patients with vitiligo and a single participation (extraction of 20 ml of
      peripheral venous blood) for the controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2015</start_date>
  <completion_date type="Actual">September 13, 2016</completion_date>
  <primary_completion_date type="Actual">September 13, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tregs levels</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tregs levels</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LRP1 (CD91) levels</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRP1 (CD91) levels</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">28</enrollment>
  <condition>VITILIGO</condition>
  <arm_group>
    <arm_group_label>Vitiligo untreated patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control. Patients without vitiligo</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CD 91 levels</intervention_name>
    <arm_group_label>Vitiligo untreated patients</arm_group_label>
    <arm_group_label>Control. Patients without vitiligo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tregs</intervention_name>
    <arm_group_label>Vitiligo untreated patients</arm_group_label>
    <arm_group_label>Control. Patients without vitiligo</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Periferic blood /serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        18 to 65 years-old both sex
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patient with vitiligo without treatment

        Exclusion Criteria:

          -  Patient with inmunosupressive disease

          -  Patient receiving vitiligo treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TREGS</keyword>
  <keyword>CD91</keyword>
  <keyword>LRP1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

